Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10

Cancer Letters
Suzanne M HectorLakshmi Pendyala

Abstract

A single cell clonal sub-line A2780/C10B that is 18-fold resistant to oxaliplatin and approximately threefold cross-resistant to cisplatin and exhibiting a metastasis associated cellular phenotype was characterized for mechanisms of resistance. The cell line exhibited a 50% reduction in the accumulation of both oxaliplatin and cisplatin relative to the parent line, while extensive decline in Pt-DNA adduct levels occurred only following oxaliplatin treatment. The basal GSH levels were fivefold higher in A2780/C10B compared to A2780 and had a fivefold elevation in gamma-GT suggesting this may be the mechanism involved in GSH elevation. The basal levels of ERCC-1, XPA and MRP-2 mRNA levels in A2780/C10B were not higher than those in A2780. The highly reduced Pt-DNA adduct formation only for oxaliplatin, but not cisplatin may be a reflection of the fact that at equimolar concentrations oxaliplatin makes fewer Pt-DNA adducts than cisplatin. The data indicate that multiple lesions occur in a single cell to produce the resistant phenotype.

References

Nov 6, 1995·Cancer Letters·L PendyalaP J Creaven
Jul 7, 1995·The Journal of Biological Chemistry·A Sancar
Jan 1, 1994·Cancer Treatment and Research·P A Andrews
Jan 1, 1996·Annual Review of Biochemistry·A Sancar
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·D A DelmastroS G Chaney
Dec 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CholletE Cvitkovic
Apr 1, 1997·Current Opinion in Genetics & Development·T LindahlR D Wood
Nov 6, 1998·Molecular Pharmacology·J M WoynarowskiP Juniewicz
Feb 19, 1999·Biochimica Et Biophysica Acta·J M WoynarowskiM C Herzig
Feb 11, 2000·Clinical Pharmacokinetics·F LéviG Milano
Oct 20, 2000·Molecular Pharmacology·J M WoynarowskiP E Juniewicz
Jan 5, 2002·Cancer Chemotherapy and Pharmacology·S HectorL Pendyala
Mar 22, 2002·The Lancet Oncology·R C Rintoul, T Sethi
Mar 27, 2002·Clinical Science·Robert C Rintoul, Tariq Sethi
Jul 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MishimaS B Howell
Mar 22, 2003·Expert Review of Anticancer Therapy·Tony Elliott, Tariq Sethi
Dec 18, 2003·The Journal of Clinical Investigation·Raghu Kalluri, Eric G Neilson
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Goli SamimiStephen B Howell
Sep 21, 2004·Cancer Chemotherapy and Pharmacology·Goli SamimiStephen B Howell
Oct 2, 2004·Journal of Inorganic Biochemistry·Roohangiz SafaeiStephen B Howell

❮ Previous
Next ❯

Citations

Mar 27, 2009·Cancer Chemotherapy and Pharmacology·Ramakumar TummalaLakshmi Pendyala
Jan 13, 2018·Reproductive Sciences·Burak ZeybekMostafa A Borahay
Mar 25, 2014·Molecular Pharmaceutics·Emma E RamsayPierre J Dilda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
S Y SharpL R Kelland
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
S ArnouldS Guichard
© 2021 Meta ULC. All rights reserved